Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
European Journal of Cancer2017Vol. 83, pp. 106–115
Citations Over TimeTop 11% of 2017 papers
Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, Sara Lonardi, Alberto Zaniboni, Paolo Marchetti, Francesco Leone, Domenico Bilancia, Rosario Vincenzo Iaffaioli, Vittorina Zagonel, Monica Giordano, Domenico Corsi, Francesco Ferraù, Roberto Labianca, Monica Ronzoni, Mario Scartozzi, Francesca Galli, Stefano Cascinu, Gerardo Rosati, Domenico Bilancia, Guglielmo Nasti, Rosario Vincenzo Iaffaioli, Sara Lonardi, Vittorina Zagonel, Alberto Zaniboni, Paolo Marchetti, Adriana Romiti, Francesco Leone, Massimo Aglietta, Monica Giordano, Domenico Corsi, Francesco Ferraù, Roberto Labianca, Stefania Mosconi, Monica Ronzoni, Luca Gianni, Eliana Rulli, Davide Poli, Francesca Galli, Valter Torri, Irene De Simone, Francesca Galli, Felice Pasini, G. Rangoni, Raffaele Venezia, Pietro Sozzi, Antonio Nuzzo, Rossana Berardi, Luciano Frontini, S. Rota, Lorena Cozzi
Related Papers
- The Efficacy and Toxicity of FOLFOX Regimen（A Combination of Leucovorin and Fluorouracil with Oxaliplatin）as First-Line Treatment of Metastatic Colorectal Cancer(2009)
- → Adjuvant FOLFOX Treatment for Stage III Colorectal Cancer: Why Patients Quit FOLFOX?(2017)
- → TARGETED THERAPY IN COMPREHENSIVE MANAGEMENT OF METASTATIC COLON CANCER(2017)
- Oxaliplatin, 5-Fluorouracil, Leucovorin 복합항암화학요법 중에 발생한 간질성 폐질환 1예(2010)
- → Randomized Trial of FOLFOX 4 and FOLFIRI in The Treatment of Advance Colorectal Cancer(2023)